Cancer-associated fibroblasts (CAFs) are central players in the microenvironment of solid
tumors, affecting cancer progression and metastasis. CAFs have diverse phenotypes …

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Despite centuries since the discovery and study of cancer, cancer is still a lethal and
intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much …

The energy metabolism of tumor cells is considered one of the hallmarks of cancer because
it is different from normal cells and mainly consists of aerobic glycolysis, fatty acid oxidation …

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis due to the lack
of methods or biomarkers for early diagnosis and its resistance to conventional treatment …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …

The lack of response to therapy in pancreatic ductal adenocarcinoma (PDAC) patients has
contributed to PDAC having one of the lowest survival rates of all cancer types. The poor …

Image-guided nanotheranostics have the potential to represent a new paradigm in the
treatment of cancer. Recent developments in modern imaging and nanoparticle design offer …

Pancreatic cancer (PC) is a lethal type of cancer for which effective therapies are limited.
Long non‑coding RNAs (lncRNAs) represent a critical type of regulator category, mediating …

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with insidious onset
and early distal metastasis. Metabolic reprogramming, the autonomous changes in cellular …